Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 1/20 | 0.69 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.69 |
| ▸ | VNN1 | O95497 | 13/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.34 |
| ▸ | RRM1 | P23921 | 1/20 | 0.33 |
| ▸ | TACR1 | P25103 | 1/20 | 0.33 |
| ▸ | TACR3 | P29371 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7042139 | 1.00 | PTGS1 (0.69) | PTGS1KCNH2VNN1MEN1USP2 | |
| SCHEMBL18812079 | 0.91 | PTGS1 (0.58) | PTGS1KCNH2VNN1ALDH1A1 | |
| SCHEMBL24093831 | 0.91 | PTGS1 (0.58) | PTGS1KCNH2VNN1ALDH1A1 | |
| SCHEMBL13326327 | 0.91 | PTGS1 (0.58) | PTGS1KCNH2VNN1ALDH1A1 | |
| SCHEMBL17742153 | 0.89 | PTGS1 (0.75) | PTGS1KCNH2VNN1DPP7 | |
| SCHEMBL7044206 | 0.88 | PTGS1 (0.79) | PTGS1KCNH2VNN1MEN1USP2 | |
| SCHEMBL7044200 | 0.88 | PTGS1 (0.79) | PTGS1KCNH2VNN1MEN1USP2 | |
| SCHEMBL7045827 | 0.88 | PTGS1 (0.79) | PTGS1KCNH2VNN1MEN1USP2 | |
| SCHEMBL7044196 | 0.88 | PTGS1 (0.79) | PTGS1KCNH2VNN1MEN1USP2 | |
| SCHEMBL7045821 | 0.88 | PTGS1 (0.79) | PTGS1KCNH2VNN1MEN1USP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3215496-B1 | PANTOTHENAMIDE ANALOGUES | RADBOUD UNIV MEDISCH CENTRUM (NL) | 2019-01-02 | — | — | EP | disclosed |
| US-9585891-B2 | Alpha hydroxy amides | MERCK PATENT GMBH (DE) | 2017-03-07 | — | — | US | disclosed |
| US-9585891-B2 | Alpha hydroxy amides | MERCK PATENT GMBH (DE) | 2017-03-07 | — | — | US | disclosed |
| US-9585891-B2 | Alpha hydroxy amides | MERCK PATENT GMBH (DE) | 2017-03-07 | — | — | US | disclosed |
| WO-2016072854-A2 | PANTOTHENAMIDE ANALOGUES | RADBOUD UNIVERSITAIR MEDISCH CENTRUM (NL) | 2016-05-12 | — | — | WO | disclosed |
| US-20150250792-A1 | ALPHA HYDROXY AMIDES | MERCK PATENT GMBH (DE) | 2015-09-10 | — | — | US | disclosed |
| US-20150250792-A1 | ALPHA HYDROXY AMIDES | MERCK PATENT GMBH (DE) | 2015-09-10 | — | — | US | disclosed |
| US-20150250792-A1 | ALPHA HYDROXY AMIDES | MERCK PATENT GMBH (DE) | 2015-09-10 | — | — | US | disclosed |
| EP-2900633-A1 | ALPHA HYDROXY AMIDES | Merck Patent GmbH (DE) | 2015-08-05 | — | — | EP | disclosed |
| CN-104703965-A | Alpha hydroxy amides | MERCK PATENT GMBH | 2015-06-10 | — | — | CN | disclosed |
| US-8969576-B2 | Substituted N-aryl pyridinones | AUSPEX PHARMACEUTICALS, INC. (US) | 2015-03-03 | — | — | US | disclosed |
| EP-1495034-A2 | MIMICS OF ACYL COENZYME-A COMPRISING PANTOLACTONE AND PANTOTHENIC ACID DERIVATIVES, COMPOSITIONS THEREOF, AND METHODS OF CHOLESTEROL MANAGEMENT AND RELATED USES | Esperion Therapeutics, Inc. (US) | 2005-01-12 | — | — | EP | disclosed |
| US-20030236213-A1 | Mimics of acyl coenzyme-A comprising pantolactone and pantothenic acid derivatives, compositions thereof, and methods of cholesterol management and related uses | ESPERION THERAPEUTICS | 2003-12-25 | — | — | US | disclosed |
| WO-2003087040-A2 | MIMICS OF ACYL COENZYME-A COMPRISING PANTOLACTONE AND PANTOTHENIC ACID DERIVATIVES, COMPOSITIONS THEREOF, AND METHODS OF CHOLESTEROL MANAGEMENT AND RELATED USES | ESPERION THERAPEUTICS, INC. (US) | 2003-10-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030236213-A1 | Mimics of acyl coenzyme-A comprising pantolactone and pantothenic acid derivatives, compositions thereof, and methods of cholesterol management and related uses | COASY, HMGCR, ACACA | PTGS1 507/4885KCNH2 3333/4885VNN1 95/4885 |
| US-20150250792-A1 | ALPHA HYDROXY AMIDES | HCAR1, NAA40, HCAR2 | PTGS1 271/4885KCNH2 1654/4885VNN1 2285/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.